Incidence, prevalence and mortality of inflammatory bowel disease in New Zealand 2006–2022 using hospital information in the Integrated Data Infrastructure ( IDI )
- 13 December 2025
- journal article
- Published by Wiley in Internal Medicine Journal
- Vol. 56 (2) , 229-237
Abstract
Introduction: The epidemiology of inflammatory bowel disease (IBD) in New Zealand (NZ) has been explored in regional studies but not at a national level. This study aimed to use administrative data to define the first nationwide IBD population and estimate the incidence, prevalence and mortality of IBD in NZ. Methods: The Integrated Data Infrastructure (IDI) is a statistical database linking population‐level health data. An IBD population was created within the IDI using hospital discharge information by International Classification of Diseases, Tenth Revision code. Incidence and prevalence rates were calculated for 16 years (2006/07–2021/22) by age, sex, ethnicity and urban/rural location. Age‐sex‐standardised mortality was measured annually from 2012 to 2022. Results: Between 1 July 2021 and June 30 2022, 19 566 people in the IDI were identified as having IBD, giving a prevalence of 391.4 (95% confidence interval (CI) 386.0–396.9) per 100 000 people. The prevalence of Crohn's disease (CD), 206.9 (95% CI 203.0–211.0), was similar to that of ulcerative colitis (UC), 213.2 (95% CI 209.2–217.2), both per 100 000 people. In the same year, 1407 new cases of IBD were observed, giving an incidence rate of 28.1 (95% CI 26.7–29.7) per 100 000 person‐years. The 2012–2022 standardised mortality ratio for IBD was 1.69 (95% CI 1.60–1.79). Conclusions: A high incidence and prevalence of IBD were seen in NZ, and increased all‐cause mortality rates were observed. Despite the limitations of using hospital data, this work established the value of IDI data for IBD epidemiological studies and produced national estimates of IBD burden.Keywords
This publication has 26 references indexed in Scilit:
- Incidence of Inflammatory Bowel Disease in Canterbury, New Zealand, 2018–2023Digestive Diseases and Sciences, 2025
- Commentary on the Epidemiology of Inflammatory Bowel Disease in Compounding Prevalence Nations: Toward Sustaining Healthcare DeliveryGastroenterology, 2024
- Associations between type 1 diabetes and educational outcomes: an Aotearoa/New Zealand nationwide birth cohort study using the Integrated Data InfrastructureDiabetologia, 2023
- Incidence of Inflammatory Bowel Disease in New Zealand Remains High, Findings in the Manawatū RegionDigestive Diseases and Sciences, 2023
- Urban–Rural Differences in Health Care Utilization for Inflammatory Bowel Disease in the USA, 2017Digestive Diseases and Sciences, 2021
- Private choices, public costs: Evaluating cost-shifting between private and public health sectors in New ZealandHealth Policy, 2021
- The four epidemiological stages in the global evolution of inflammatory bowel diseaseNature Reviews Gastroenterology & Hepatology, 2020
- The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet Gastroenterology & Hepatology, 2020
- Environmental triggers in IBD: a review of progress and evidenceNature Reviews Gastroenterology & Hepatology, 2017
- Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort StudyAmerican Journal of Gastroenterology, 2017